N-[2-(二甲基氨基)乙基]丁酰胺 | 63224-16-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: N-[2-(二甲基氨基)乙基]丁酰胺
• 英文名称: Dimethyl-β-butyrylaminoethylamine
• 英文别名: N-<2-(dimethylamino)ethyl>butyramide；N-(2-(dimethylamino)ethyl)butyramide；N-[2-(dimethylamino)ethyl]butanamide；N-(2-Dimethylamino-aethyl)-butyramid；Butanamide, N-(2-(dimethylamino)ethyl)-
• CAS: 63224-16-8
• 化学式: C₈H₁₈N₂O
• mdl: MFCD01740843
• 分子量: 158.244
• InChiKey: GXQRNXRDAOAFDO-UHFFFAOYSA-N

物化性质

• 沸点：
  126-132 °C(Press: 11-12 Torr)
• 密度：
  0.910±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  溴代十二烷 、 N-[2-(二甲基氨基)乙基]丁酰胺 生成 2-(butanoylamino)ethyl-dodecyl-dimethylazanium;bromide
  参考文献：
  名称：

  CSIBA, I.;LACKO, I.;BITTEREDOVA, F.;MLYNARCIK, D., CS. FARM., 36,(1987) N 8, 349-354

  摘要：

  DOI：
• 作为产物：
  描述：

  N,N-二甲基乙二胺 、 丁酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以61 %的产率得到N-[2-(二甲基氨基)乙基]丁酰胺
  参考文献：
  名称：

  丁酸和戊酸二甲氨基烷基酰胺的合成及其在环氧树脂聚合中的活性研究

  摘要：

  通过N , N-二甲基氨基烷基胺的酰化反应得到了多种丁酸和戊酸的氨基酰胺。研究了合成的氨基酰胺在商用环氧树脂 ED-20 硬化反应中的活性。基于差热分析和红外傅里叶光谱的数据，以及考虑到硬化组合物中凝胶部分的含量，发现硬化剂的活性随着二胺中烃链的长度而增加片段增加，氨基酰胺分子中的总氮含量减少。

  DOI：

  10.1007/s11172-023-4092-7

文献信息

• Polarity-Tuning Derivatization-LC-MS Approach for Probing Global Carboxyl-Containing Metabolites in Colorectal Cancer
  作者：Xiqing Bian、Na Li、Binbin Tan、Baoqing Sun、Ming-Quan Guo、Guoxin Huang、Li Fu、W. L. Wendy Hsiao、Liang Liu、Jian-Lin Wu

  DOI：10.1021/acs.analchem.8b01873

  日期：2018.10.2

  Carboxyl-containing metabolites (CCMs) widely exist in living systems and are the essential components for life. Global characteristics of CCMs in biological samples are critical for the understanding of physiological processes and the discovery for the onset of relevant diseases. However, their determination represents a challenge due to enormous polarity differences, structural diversity, high structural similarity, and poor ionization efficiency in mass spectrometry. Herein, 5-(diisopropylamino)amylamine (DIAAA) derivatization coupled with liquid chromatography–mass spectrometry (LC-MS) was developed for mapping the CCMs. With this methodology, the sensitivity was significantly enhanced. More importantly, the hydrophobicity of polar CCMs, amino acids, TCA cycle intermediates, and short-chain fatty acids and the hydrophilicity of low-polar CCMs, long-chain fatty acids, and bile acids were significantly increased, resulting in a remarkable separation efficiency for which 68 CCMs can be simultaneously determined. Furthermore, the polarity-tuning effect was confirmed to be induced by the different impacts of aliphatic chains and nitrogen atom in DIAAA, the latter existing as a cation in the acidic mobile phase, using different derivatization reagents. Finally, this derivatization method was utilized to hunt for the potential biomarkers in colorectal cancer (CRC) patients and 52 CCMs, related with several key metabolic pathways, including amino acids metabolism, TCA cycle, fatty acid metabolism, pyruvate metabolism, and gut flora metabolism were identified. This innovative polarity-tuning derivatization-LC-MS approach was proved to be a valuable tool for probing global metabolome with high separation efficiency and sensitivity in various biological samples.

  含羧基代谢物（CCMs）广泛存在于生物系统中，是生命的基本组成部分。CCMs在生物样本中的全球特征对于理解生理过程和发现相关疾病的发生具有重要意义。然而，由于极性差异巨大、结构多样性、高结构相似性和在质谱中的离子化效率较低，它们的测定面临挑战。在此，我们开发了5-(二异丙基氨基)戊胺（DIAAA）衍生化结合液相色谱-质谱（LC-MS）的方法以绘制CCMs的分布。通过这种方法，灵敏度显著提高。更重要的是，极性CCMs、氨基酸、TCA循环中间体和短链脂肪酸的疏水性显著增强，而低极性CCMs、长链脂肪酸和胆汁酸的亲水性也显著增加，从而实现了卓越的分离效率，使得68种CCMs可以同时测定。此外，极性调节效应被证实是由于DIAAA中脂肪链和氮原子的不同影响所引起的，后者在酸性流动相中以阳离子的形式存在，使用不同的衍生化试剂。最后，该衍生化方法被用于寻找结直肠癌（CRC）患者的潜在生物标志物，识别出52种与多条关键代谢通路（包括氨基酸代谢、TCA循环、脂肪酸代谢、丙酮酸代谢和肠道菌群代谢）相关的CCMs。这种创新的极性调节衍生化-LC-MS方法被证明是探测各种生物样本全球代谢组的高分离效率和灵敏度的有价值工具。
• Synthesis of Reversible Inhibitors of Acetylcholinesterase (EC 3.1.1.7)
  作者：Peter Thanei-Wyss、Peter G. Waser

  DOI：10.1002/hlca.19830660731

  日期：1983.11.2

  The synthesis and characterization of some reversible acetylcholinesterase inhibitors are described in detail. They are structurally related to the natural substrate acetylcholine. All of them bear a trimethylammonium moiety as ‘cationic head’. Instead of an electrophilic ester group, the title compounds include a variety of functionalities, such as halide, ether, thioether, epoxide, amide, ketone

  详细描述了一些可逆的乙酰胆碱酯酶抑制剂的合成和表征。它们在结构上与天然底物乙酰胆碱有关。它们全部带有三甲基铵部分作为“阳离子头”。代替亲电子酯基，标题化合物包括各种官能团，例如卤化物，醚，硫醚，环氧化物，酰胺，酮和双键。因此，这些物质适合用作研究乙酰胆碱酯酶活性中心的酯基亚位点的探针。
• 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases
  申请人：Bloomfield Graham Charles

  公开号：US20080280871A1

  公开（公告）日：2008-11-13

  in free or salt form, wherein R a , R b , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  在自由或盐形式中，其中Ra，Rb，R2，R3，R4和R5具有规范中指示的含义，对于治疗由磷脂酰肌醇3-激酶介导的疾病是有用的。还描述了含有该化合物的药物组合物以及制备该化合物的过程。
• 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：Bloomfield Graham Charles

  公开号：US20110124624A1

  公开（公告）日：2011-05-26

  Compounds of Formula I: in free or salt form, wherein R a , R b , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式I的化合物：以自由或盐形式存在，其中Ra、Rb、R2、R3、R4和R5的含义如规范中所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• MACROMOLECULES OF DENDRIMER-PLATINUM CONJUGATES
  申请人：STARPHARMA PTY LTD.

  公开号：US20160220689A1

  公开（公告）日：2016-08-04

  A macromolecule comprising a dendrimer having surface amino groups to which at least one platinum-containing moiety is attached is provided. The macromolecule may have a plurality of platinum-containing moieties attached to the surface amino groups. Alternatively, the macromolecule may comprise a dendrimer having surface amino groups to which at least two different moieties are attached, a first moiety being a platinum-containing moiety and the second moiety being a pharmacokinetic modifying agent or targeting agent. Pharmaceutical compositions comprising the macromolecules and uses of the macromolecules for treating or suppressing the growth of a cancer is also described.

  本发明提供了一种大分子，包括具有表面氨基团的树状分子，至少一个含铂基团附着于其上。该大分子可以具有多个附着在表面氨基团上的含铂基团。或者，该大分子可以包括具有表面氨基团的树状分子，至少附着有两种不同的基团，第一种基团是含铂基团，第二种基团是药物动力学修饰剂或靶向剂。还描述了包括该大分子的制药组合物以及使用该大分子治疗或抑制癌症生长的用途。